Zeus Capital completes the year’s largest pharmaceutical AIM IPO
12th December 2014
Zeus Capital has acted as nominated adviser and broker to Quantum Pharma on its AIM IPO and £100m fundraise, giving the business a market capitalisation on admission of £125m – the largest pharmaceutical listing on the market in 2014.
Quantum, based in County Durham and founded in 2005, is a market-leading manufacturer, supplier and service provider within the niche pharmaceutical sector, providing its range of 22,000 products to around 6,750 major UK pharmacy chains, wholesalers and hospitals.
The listing on AIM has helped the company restructure the balance sheet, raise further capital for the business to increase the rate of development of a portfolio of niche pharmaceutical products and make strategic acquisitions.
Andrew Scaife, Managing Director at Quantum Pharma, commented:
“Our decision to list on AIM makes both strategic and commercial sense as we take Quantum to the next stage of its development. We are delighted to see such high levels of institutional demand and we now look forward to working with our new institutional shareholders.”
Dominic Wilson, Head of Healthcare at Zeus Capital, commented:
“Zeus Capital is very pleased to have been involved in the £125m flotation of this high-quality, cash-generative, niche pharmaceutical business. We look forward to seeing the management team accelerate the growth of the business now it owns 100% of Colonis, its drug development division. Additionally, we welcome Quantum’s desire to continue to provide the most efficient, high-quality, service into the hospital, pharmacy, care home and home care market throughout the UK.”